Development of Salvianolic acid B-Tanshinone II A-Glycyrrhetinic acid compound liposomes: Formulation optimization and its effects on proliferation of hepatic stellate cells

International Journal of Pharmaceutics

Volumn 462, Issue 1-2, 2014, Pages 11-18

  Lin, Jiahao ^a   Wang, Xiuli ^a   Wu, Qing ^a   Dai, Jundong ^a   Guan, Huida ^a   Cao, Weiyi ^a   He, Liangying ^a   Wang, Yurong ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Co delivery; Glycyrrhetinic acid; Hepatic stellate cells; Liposomes; Salvianolic acid B; Tanshinone II A

Indexed keywords

GLYCYRRHETINIC ACID; LIPID; LIPOSOME; SALVIANOLIC ACID B; TANSHINONE IIA;

ARTICLE; BIOLOGICAL ACTIVITY; BOX BEHNKEN DESIGN; CELL ENCAPSULATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG DETERMINATION; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUTION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; INVESTIGATIVE PROCEDURES; LIPOSOMAL DELIVERY; ORTHOGONAL TEST; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE FACTOR TEST; STELLATE CELL; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

CO-DELIVERY; GLYCYRRHETINIC ACID; GLYCYRRHETINIC ACID (PUBCHEM CID: 10114); HEPATIC STELLATE CELLS; LIPOSOMES; SALVIANOLIC ACID B; SALVIANOLIC ACID B (PUBCHEM CID: 13991587); TANSHINONE II A; TANSHINONE II A (PUBCHEM CID: 164676);

BENZOFURANS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; DELAYED-ACTION PREPARATIONS; DITERPENES, ABIETANE; GLYCYRRHETINIC ACID; HEPATIC STELLATE CELLS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIPOSOMES; MICROSCOPY, ELECTRON, TRANSMISSION; PARTICLE SIZE; TIME FACTORS;

EID: 84892155656     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.12.040     Document Type: Article

References (39)

1. R. Bataller, and D.A. Brenner Liver fibrosis J. Clin. Invest. 115 2005 209 218 (Pubitemid 40385459)
2. M.A. Bezerra, R.E. Santelli, E.P. Oliveira, L.S. Villar, and L.A. Escaleira Response surface methodology (RSM) as a tool for optimization in analytical chemistry Talanta 76 2008 965 977
3. X.H. Che, E.J. Park, Y.Z. Zhao, W.H. Kim, and D.H. Sohn Tanshinone II A induces apoptosis and s phase cell cycle arrest in activated rat hepatic stellate cells Basic Clin. Pharmacol. Toxicol. 106 2010 30 37
4. C. Chen, D. Han, C. Cai, and X. Tang An overview of liposome lyophilization and its future potential J. Control. Release 142 2010 299 311
5. A. Ćurić, R. Reul, J. Möschwitzer, and G. Fricker Formulation optimization of itraconazole loaded PEGylated liposomes for parenteral administration by using design of experiments Int. J. Pharm. 448 2013 189 197
6. X. Deng, Q. Wang, X. Zhang, Y. Liu, Y. Zeng, L. Jia, P. Li, and D. Cai Effective mechanism of the glycyrrhetinic acid with tanshinones on immunological liver fibrosis in rat China Pharm. 10 2007 741 744
7. FDA Liposome drug products, chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation (draft guidance) Guid. Ind. 67 2002 54220
8. FDA Draft Guidance on Doxorubicin Hydrochloride 2010 FDA
9. S.L. Friedman Mechanisms of hepatic fibrogenesis Gastroenterology 134 2008 1655 1669 (Pubitemid 351615417)
10. C. Hou Observation of the therapeutic effects of compound glycyrrhizin combined with radix salviae miltiorrhizae on hepatic fibrosis China Pharm. 16 2005 53
11. H. Hyun Kim, J. Kim, H. Young Ji, Y. Chul Kim, D. Hwan Sohn, B. Mu Lee, and H. Suk Lee Pharmacokinetics of lithospermic acid B isolated from Salvia miltiorrhiza in rats J. Toxicol. Environ. Health A 68 2005 2239 2247 (Pubitemid 41755680)
12. ICH Stability Testing of New Drug Substances and Products Q1A (R2) 2003 ICH
13. W. Kleppmann Taschenbuch Versuchsplanung: Produkte und Prozesse optimieren 2008 Hanser Verlag
14. M. Levy, and S. Benita Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model Int. J. Pharm. 66 1990 29 37
15. J. Li, P. Liu, J.-P. Liu, J.-K. Yang, W.-L. Zhang, Y.-Q. Fan, S.-L. Kan, Y. Cui, and W.-J. Zhang Bioavailability and foam cells permeability enhancement of salvianolic acid B pellets based on drug-phospholipids complex technique Eur. J. Pharm. Biopharm. 83 2012 76 86
16. Y. Li The therapeutic effects of compound glycyrrhizin combined with radix salviae miltiorrhizae on hepatic fibrosis Proc. Clin. Med. J. 2007 16
17. L.H. Lian, E.J. Park, H.S. Piao, Y.Z. Zhao, and D.H. Sohn Aloe emodin-induced apoptosis in t-HSC/Cl-6 cells involves a mitochondria-mediated pathway Basic Clin. Pharmacol. Toxicol. 96 2005 495 502 (Pubitemid 40835706)
18. L. Lin, W. Wang, and Y. Niu Determination of entrapment efficiency for fluorescence red GG liposomes by low-speed centrifugation J. Zhejiang Univ. Technol. 37 2009 535 537
19. Y.L. Lin, Y.C. Hsu, Y.T. Chiu, and Y.T. Huang Antifibrotic effects of a herbal combination regimen on hepatic fibrotic rats Phytother. Res. 22 2008 69 76
20. P. Liu, Y.-Y. Hu, C. Liu, D.-Y. Zhu, H.-M. Xue, Z.-Q. Xu, L.-M. Xu, C.-H. Liu, H.-T. Gu, and Z.-Q. Zhang Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B World J. Gastroenterol. 8 2002 679 685 (Pubitemid 34918663)
21. S. Liu, D. Peng, P. Li, and R. Xiang Study on components and compatibility of medicines of youhuaganshen compound in resisting hepatic fibrosis China J. Tradit. Chin. Med. Pharm. 20 2005 373 375
22. J.M. Luk, Q.S. Zhang, N.P. Lee, J.Y. Wo, P.P. Leung, L.X. Liu, M.Y. Hu, K.F. Cheung, C.K. Hui, and G.K. Lau Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model Liver Int. 27 2007 548 557 (Pubitemid 46534577)
23. W.-C. Ma, Q. Zhang, H. Li, C.A. Larregieu, N. Zhang, T. Chu, H. Jin, and S.-J. Mao Development of intravenous lipid emulsion of α-asarone with significantly improved safety and enhanced efficacy Int. J. Pharm. 450 2013 21 30
24. R.H. Myers, and C.M. Anderson-Cook Response Surface Methodology: Process and Product Optimization Using Designed Experiments 2009 Wiley Wiley.com
25. M. Sheng-Jun, B. Yue-Qi, J. Hui, W. Da-Peng, H. Ru, and H. Shi-Xiang Preparation, characterization and uptake by primary cultured rat hepatocytes of liposomes surface-modified with glycyrrhetinic acid Pharmazie 62 2007 614 619 (Pubitemid 47326169)
26. B. Singh, R. Kapil, M. Nandi, and N. Ahuja Developing oral drug delivery systems using formulation by design: vital precepts, retrospect and prospects Expert Opin. Drug Deliv. 8 2011 1341 1360
27. D. Volodkin, H. Mohwald, J.-C. Voegel, and V. Ball Coating of negatively charged liposomes by polylysine: drug release study J. Control. Release 117 2007 111 120 (Pubitemid 46161871)
28. J.Y. Wang, Q.S. Zhang, J.S. Guo, and M.Y. Hu Effects of glycyrrhetinic acid on collagen metabolism of hepatic stellate cells at different stages of liver fibrosis in rats World J. Gastroenterol. 7 2001 115 119 (Pubitemid 32170910)
29. Q.-L. Wang, Y.-Y. Tao, J.-L. Yuan, L. Shen, and C.-H. Liu Salvianolic acid B prevents epithelial-to-mesenchymal transition through the TGF-β1 signal transduction pathway in vivo and in vitro BMC Cell Biol. 11 2010 31
30. T. Wang, Y. Deng, Y. Geng, Z. Gao, J. Zou, and Z. Wang Preparation of submicron unilamellar liposomes by freeze-drying double emulsions Biochim. Biophys. Acta 1758 2006 222 231 (Pubitemid 44294663)
31. X. Wang, Z.R. Zhang, H. Fu, J. Liu, Q. Chen, Y. Nie, L. Deng, and T. Gong Simultaneous determination and pharmacokinetic study of water-soluble and lipid-soluble components of danshen in rat plasma using HPLC-UV method Biomed. Chromatogr. 21 2007 1180 1185 (Pubitemid 350200898)
32. Y.-T. Wu, Y.-F. Chen, Y.-J. Hsieh, I. Jaw, M.-S. Shiao, and T.-H. Tsai Bioavailability of salvianolic acid B in conscious and freely moving rats Int. J. Pharm. 326 2006 25 31 (Pubitemid 44647741)
33. X. Xu, M.A. Khan, and D.J. Burgess A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment Int. J. Pharm. 419 2011 52 59
34. S. Yang, J. Chen, D. Zhao, D. Han, and X. Chen Comparative study on preparative methods of DC-Chol/DOPE liposomes and formulation optimization by determining encapsulation efficiency Int. J. Pharm. 434 2012 155 160
35. B. Yu, Z. Zhang, and W. Liu Method to improve entrapment efficiency of liposomes Chin. J. Pharm. 33 2002 564 568
36. H. Yu, L. Teng, Q. Meng, Y. Li, X. Sun, J. Lu, J. Lee, and R.L. Teng Development of liposomal Ginsenoside Rg3: formulation optimization and evaluation of its anticancer effects Int. J. Pharm. 450 2013 250 258
37. C. Zhang, W. Wang, T. Liu, Y. Wu, H. Guo, P. Wang, Q. Tian, Y. Wang, and Z. Yuan Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy Biomaterials 33 2012 2187 2196
38. X. Zhao, J. Liu, Y. Hu, Y. Fan, D. Wang, J. Yuan, L. Xu, L. Cui, and Z. Jing Optimization on condition of glycyrrhetinic acid liposome by RSM and the research of its immunological activity Int. J. Biol. Macromol. 51 2012 299 304
39. L. Zhou, M.S. Chow, and Z. Zuo Effect of sodium caprate on the oral absorptions of danshensu and salvianolic acid B Int. J. Pharm. 379 2009 109 118